2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Metabolic Diseases D008659 12 associated lipids
Phenylketonurias D010661 7 associated lipids
Hyperoxaluria D006959 3 associated lipids
Canavan Disease D017825 2 associated lipids
Tyrosinemias D020176 2 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Choi C et al. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. 2013 NMR Biomed pmid:23592268
Nota B et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. 2013 Am. J. Hum. Genet. pmid:23561848
Wang F et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. 2013 Science pmid:23558173
Rohle D et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. 2013 Science pmid:23558169
Juratli TA et al. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. 2013 Neuro-oncology pmid:23410661
Losman JA et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. 2013 Science pmid:23393090
Tomlinson L et al. Cannabinoid receptor antagonist-induced striated muscle toxicity and ethylmalonic-adipic aciduria in beagle dogs. 2012 Toxicol. Sci. pmid:22821849
Durán RV and Hall MN Glutaminolysis feeds mTORC1. 2012 Cell Cycle pmid:23095634
Lazovic J et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. 2012 Neuro-oncology pmid:23090985
Fathi AT et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. 2012 Blood pmid:23074281
Grassian AR et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). 2012 J. Biol. Chem. pmid:23038259
Yang H et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. 2012 Clin. Cancer Res. pmid:23071358
Sasaki M et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. 2012 Genes Dev. pmid:22925884
Yang M et al. The emerging role of fumarate as an oncometabolite. 2012 Front Oncol pmid:22866264
Farias FH et al. A L2HGDH initiator methionine codon mutation in a Yorkshire terrier with L-2-hydroxyglutaric aciduria. 2012 BMC Vet. Res. pmid:22834903
Riedel TJ et al. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. 2012 Biochim. Biophys. Acta pmid:22771891
Smolková K and Ježek P The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. 2012 Int J Cell Biol pmid:22675360
Maier A et al. Transgenic Introduction of a Glycolate Oxidative Cycle into A. thaliana Chloroplasts Leads to Growth Improvement. 2012 Front Plant Sci pmid:22639647
Leonardi R et al. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. 2012 J. Biol. Chem. pmid:22442146
Kalinina J et al. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. 2012 J. Mol. Med. pmid:22426639
Chotirat S et al. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. 2012 J Hematol Oncol pmid:22397365
Kranendijk M et al. Progress in understanding 2-hydroxyglutaric acidurias. 2012 J. Inherit. Metab. Dis. pmid:22391998
Constantin A et al. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. 2012 Artif Intell Med pmid:22387185
Kunimoto H et al. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. 2012 Sci Rep pmid:22355785
Lu C et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. 2012 Nature pmid:22343901
Koivunen P et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. 2012 Nature pmid:22343896
Kleessen S et al. Model-based confirmation of alternative substrates of mitochondrial electron transport chain. 2012 J. Biol. Chem. pmid:22334689
Chow LM and Baker SJ Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. 2012 Oncotarget pmid:22287481
Choi C et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. 2012 Nat. Med. pmid:22281806
Bleeker FE et al. Recent advances in the molecular understanding of glioblastoma. 2012 J. Neurooncol. pmid:22270850
Shaw RJ and Cantley LC Decoding key nodes in the metabolism of cancer cells: sugar & spice and all things nice. 2012 F1000 Biol Rep pmid:22242042
Elkhaled A et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. 2012 Sci Transl Med pmid:22238333
Andronesi OC et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. 2012 Sci Transl Med pmid:22238332
Muñoz-Pinedo C et al. Cancer metabolism: current perspectives and future directions. 2012 Cell Death Dis pmid:22237205
Cairns RA et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. 2012 Blood pmid:22215888
Li Y et al. Combined inactivation of the Clostridium cellulolyticum lactate and malate dehydrogenase genes substantially increases ethanol yield from cellulose and switchgrass fermentations. 2012 Biotechnol Biofuels pmid:22214220
Borger DR et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. 2012 Oncologist pmid:22180306
Luchman HA et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. 2012 Neuro-oncology pmid:22166263
Borodovsky A et al. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. 2012 Curr Opin Oncol pmid:22080945
Pope WB et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. 2012 J. Neurooncol. pmid:22015945
Ward PS et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. 2012 Oncogene pmid:21996744
Capper D et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. 2012 Int. J. Cancer pmid:21913188
Tefferi A et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. 2012 Leukemia pmid:21912393
Fathi AT and Abdel-Wahab O Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. 2012 Adv Hematol pmid:21811504
Lecoeur H et al. HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. 2012 Cell Death Dis pmid:22419111
Saccenti E et al. Simplivariate models: uncovering the underlying biology in functional genomics data. 2011 PLoS ONE pmid:21698241
Bhatia S et al. Mycosporine and mycosporine-like amino acids: A paramount tool against ultra violet irradiation. 2011 Pharmacogn Rev pmid:22279371
Scott JG et al. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? 2011 Neuro-oncology pmid:21784755
Bralten LB et al. Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. 2011 PLoS ONE pmid:21760942
Lages E et al. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. 2011 PLoS ONE pmid:21655185